Business, energy, technology, markets and global industry news from Business News Today

Keenova Therapeutics

PharmaDeviceNews Keenova Therapeutics
Mezzion’s investigational drug udenafil has reduced kidney cyst burden in an ADPKD animal study, strengthening the scientific rationale for the company’s planned Phase 2b clinical programme. Representative image.
Pharma & Biotech

Keenova’s TERLIVAZ shows kidney response in transplant-ineligible patients as new CONFIRM analysis emerges

Keenova's TERLIVAZ analysis examines kidney recovery in transplant-ineligible HRS-AKI patients as respiratory safety and survival remain key concerns.

Read More
Pharma & Biotech

Can XIAFLEX straighten hammer toe without surgery? Keenova begins pivotal US trial

Keenova has dosed the first patient in a randomized Phase 3 study evaluating whether collagenase injections can reduce fixed toe contracture and provide a nonsurgical treatment for hammer toe.

Read More
Pharma & Biotech

XIAFLEX hit its Phase 3 goals, but can Keenova change plantar fibromatosis care?

Find out how Keenova’s XIAFLEX Phase 3 success could create the first approved drug for plantar fibromatosis.

Read More